SNB-19 Xenograft Model Service for Glioblastoma

SNB-19 Xenograft Model Service for Glioblastoma --- a validated preclinical platform for evaluating therapeutic efficacy, resistance mechanisms, and tumor biology in one of the most aggressive primary brain malignancies. At Alfa Cytology, we specialize in delivering robust, reproducible SNB-19 xenograft models tailored to your preclinical research objectives. Our integrated service spans from model construction and in-life monitoring to comprehensive histopathological and molecular endpoint analysis, ensuring high-quality data to advance your glioblastoma drug development pipeline.

Overview of SNB-19 Xenograft Model for Glioblastoma

The SNB-19 xenograft model is a well-established preclinical system derived from a human glioblastoma multiforme (GBM) tumor, widely utilized to investigate tumor proliferation, therapeutic resistance, and molecular pathogenesis. Genomic profiling reveals key alterations characteristic of primary GBM, including TP53 mutation (p.Arg273His), PTEN loss, moderate EGFR expression, and TERT promoter mutation (C228T), providing a genetically relevant backdrop for translational studies. The cell line exhibits adherent, fibroblast-like morphology with a doubling time of approximately 24 hours, and demonstrates robust tumorigenicity in immunodeficient mice, making it a dependable platform for both subcutaneous and orthotopic implantation strategies.

In xenograft applications, SNB-19 forms well-circumscribed tumors with a notably low-invasive phenotype compared to more aggressive glioma lines such as U87 or U251 MG. This distinct growth pattern enables precise quantification of tumor growth inhibition and delay, while still permitting investigation of angiogenesis, apoptosis, and epigenetic modulation. The model has been instrumental in evaluating DNA-damaging agents, histone deacetylase inhibitors, mTOR pathway inhibitors, and nanoparticle-based drug delivery systems. Its responsiveness to RNA interference targeting Cathepsin B and uPAR, as well as its utility in defining treatment-resistant tumor-initiating cell populations expressing SOX2 and OCT4, underscores its value in studying recurrence mechanisms and testing novel therapeutic modalities.

Figure 1. Atranorin inhibited ZIKV infection in SNB-19 cells. (Huang, Guan-gen, et al., 2024)

Cell Line Information: SNB-19

The SNB-19 cell line is a human glioblastoma model established from the surgical resection of a left parieto-occipital glioblastoma. The following table summarizes its key biological and culture characteristics:

Our Services

Alfa Cytology offers end-to-end SNB-19 xenograft model services designed to accelerate your preclinical glioblastoma research. From initial cell line authentication and health monitoring to tumor implantation, longitudinal measurement, and terminal necropsy with comprehensive molecular profiling, our experienced scientific team ensures rigorous study execution, reproducible data generation, and seamless integration with your downstream pharmacodynamic and pharmacokinetic analyses.

Workflow of SNB-19 Xenograft Model Construction

Construction of the SNB-19 xenograft model follows a standardized, quality-controlled workflow optimized for consistent tumor engraftment, reliable growth kinetics, and clinically relevant endpoint analysis. Both subcutaneous and orthotopic configurations are available, with each step executed under strict GLP-compliant and IACUC-accredited protocols.

1. Cell Line Expansion & Quality Control: SNB-19 cells are expanded under exponential growth conditions in DMEM supplemented with 10% FBS. Prior to implantation, cells undergo comprehensive quality control including mycoplasma testing, STR authentication, and viability assessment by trypan blue exclusion (>=98% viability required).
2. Cell Preparation for Injection: Cells are harvested by trypsinization, washed, and resuspended at the appropriate density (typically 1 x 10^6 viable cells per 100 uL) in a Matrigel-cell suspension matrix to enhance engraftment stability and initial tumor establishment.
3. Animal Preparation & Randomization: Immunodeficient mice (athymic BALB/c nude or NOD/SCID, 10--12 weeks old) are acclimatized under controlled environmental conditions. Animals are randomized into treatment groups based on body weight to minimize bias.
4. Tumor Implantation: For subcutaneous models, the cell suspension is injected into the flank of the hind leg. For orthotopic models, cells are stereotactically delivered into the murine striatum to replicate anatomical and microenvironmental features of human GBM, including blood-brain barrier interactions.
5. In-Life Monitoring & Tumor Measurement: Tumor growth is monitored via digital caliper measurement for subcutaneous models, or through bioluminescence imaging and MRI for orthotopic models. Body weight, clinical signs, and tumor burden are recorded at regular intervals according to the study protocol.
6. Treatment Administration & Data Collection: Test compounds are administered according to the study design (route, frequency, and duration). Tumor dimensions and body weights are recorded throughout the study. At termination, tumors are excised, weighed, and processed for histology, biomarker analysis, and molecular profiling.
7. Data Compilation & Reporting: All raw data, statistical analyses, and representative images are compiled into a comprehensive study report, including tumor growth curves, survival analysis, biomarker expression profiles, and interpretive scientific summaries.

Figure 2. SNB-19 xenograft model construction workflow.

Case Study-SNB-19 Xenograft Model Development

In a recent internal validation study, Alfa Cytology successfully established both subcutaneous and orthotopic SNB-19 xenograft cohorts with consistent engraftment rates and predictable tumor growth kinetics. Subcutaneous tumors reached evaluable volumes within 10--14 days post-implantation, while orthotopic lesions demonstrated progressive intracranial growth monitored by bioluminescence imaging. Preliminary pharmacological testing with a reference mTOR inhibitor demonstrated dose-dependent tumor growth inhibition and modulation of downstream signaling markers. Full datasets, including detailed growth curves, survival analysis, and molecular endpoint data, are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise, rigorous quality standards, and flexible study design to deliver SNB-19 xenograft models that generate actionable preclinical insights. Our service is built around the following core strengths:

• Fully validated SNB-19 cell stocks with confirmed STR profiles, mycoplasma-negative status, and optimized culture conditions for robust tumorigenicity.
• GLP-compliant and IACUC-accredited vivarium facilities ensuring ethical, reproducible, and regulatory-quality study execution.
• Expertise in both subcutaneous and orthotopic implantation techniques, including stereotactic intracranial delivery and advanced in vivo imaging modalities.
• Comprehensive endpoint analysis encompassing histopathology, immunohistochemistry, molecular profiling, and tissue banking for retrospective biomarker studies.
• Customizable study designs accommodating monotherapy, combination therapy, dose-escalation, and survival endpoints tailored to your compound's mechanism of action.
• Dedicated project management with transparent reporting timelines, real-time data access, and collaborative scientific consultation throughout the study lifecycle.

Contact Us

Ready to advance your glioblastoma therapeutic program with a validated SNB-19 xenograft model? Contact us today to discuss your study objectives, receive a customized proposal, and learn how Alfa Cytology can deliver the high-quality preclinical data you need. Please reach out to us today via our inquiry form or email to learn more about our SNB-19 Xenograft Model services.

For research use only. Not intended for any clinical use.